Prospective randomized study comparing MEMID with a Chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma

Oncology

Volumn 69, Issue 1, 2005, Pages 19-26

  Chamorey, E ^a   Gressin, R ^b   Peyrade, F ^a   Rossi, J F ^c   Lepeu, G ^d   Foussard, C ^e   Harrousseau, J L ^f   Fabbro, M ^g   Richard, B ^h   Delwail, V ⁱ   Maisonneuve, H ^j   Vilque, J P ^k   Thyss, A ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b HÔPITAL MICHALLON   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d CENTRE HOSPITALIER D AVIGNON   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g CENTRE VAL D AURELLE   (France)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ University of Poitiers   (France)

^j Centre Hospitalier Departemental   (France)

^k SERVICE DE DERMATOLOGIE   (France)

more..

Author keywords

CEOP; Elderly; MEMID; Non Hodgkin lymphoma; Phase III study; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHYLGLYOXAL; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; EPIRUBICIN; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MITOXANTRONE; NEUTROPENIA; PREDNISONE; PROSPECTIVE STUDIES; PYRUVALDEHYDE; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE;

EID: 23944524322     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087284     Document Type: Article

References (26)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
2. Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1998;6:1838-1844.
3. Tirelli U, Zagonel V, Errante D, Fratino L, Monfardini S: Treatment of non-Hodgkin's lymphoma in the elderly: An update. Hematol Oncol 1998;16:1-13.
4. The Non-Hodgkin's Lymphoma Classification Project: Effect of age on the characteristics and clinical behaviour of non-Hodgkin's lymphoma patients. Ann Oncol 1997;8:973-978.
5. Balducci L, Repetto L: Increased risk of myelotoxicity in elderly patients with non-Hodgkin's lymphoma. Cancer 2004;1:6-11.
6. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
7. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
9. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F: Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Blood 2003;102:4284-4289.
10. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
11. Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Bjorkholm M: CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-3848.
12. Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM: CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.
13. Meyer RM, Gyger M, Langley R, Lesperance B, Caplan SN: A phase one trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998;30:591-600.
14. Doorduijn JK, Van Der Holt B, Van Imhoff GW, et al: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3045.
15. Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A, Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G, Pogliani E, et al: A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995;80:318-324.
16. Basaran M, Bavbek ES, Sakar B, Eralp Y, Alici S, Tas F, Yaman F, Dogan O, Camlica H, Onat H: Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): A phase II study. Am J Clin Oncol 2001;24:570-575.
17. Rossi JF, Fabbro M, Gaspard MH, et al: Aggressive non-Hodgkin's lymphoma in elderly patients treated with MEMID protocol. Congress of the American Society of Hematology (abstract). Blood 1993;82:2288.
18. Fabbro M, Peray P, Thyss A, Legouffe E, Rossi JF: Aggressive non-Hodgkin's lymphomas in elderly: Dose intensity with MEMID chemotherapy and recombinant human granulocyte-macrophage colony-stimulating-factor support in a phase II study. European Society of Medical Oncology Congress 1994, Lisbon, abstract 302.
19. The Non-Hodgkin's Lymphoma Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
20. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
21. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, World Health Organization, 1979.
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Ihaka R, Gentleman R: R: A language for data analysis and graphics. J Comput Graph Statist 1996;5:299-314.
24. Thyss A, Gressin R, Foussard C, Lepeu G, Fabbro M, Delwail V, Vilque JP, Haroussau JL, Rossi JF: Phase III study of CHOP-like regimen compared with MEMID in elderly patients with aggressive Hodgkin's lymphoma: Preliminary results. Congress of the American Society of Hematology (abstract). Blood 1998;92:1099.
25. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A, Rübe C, Rudolph C, Reiser M, Hossfeld D, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, and the German High-Grade Non-Hodgkin's Lymphoma Study Group: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-641.
26. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.